Chemren Bio-Engineering Co., Ltd.

Products > Others > > GDC-0068
Product name : GDC-0068
Item : CR1211
CAS : 1001264-89-6
 Enlarge Image                   Back
←[Previous Product]              [Next Product]→


Biological Activity of GDC-0068

GDC-0068(RG 7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, 620-fold selectivity over PKA.
IC50 value: 5 nM/18 nM/8 nM(Akt1/2/3) [1]
Target: Akt1/2/3
in vitro: Testing against a broad panel of 230 kinases, GDC-0068 only inhibits 3 kinases by >70% at 1 μM concentration (PRKG1α, PRKG1β, and p70S6K, with IC50 of 98 nM, 69 nM, and 860 nM, respectively). GDC-0068 displays >100-fold selectivity for Akt over PKA with IC50 of 3.1 μM. In LNCaP, PC3 and BT474M1 cells, GDC-0068 treatment inhibits the phosphorylation of the Akt substrate, PRAS40 with IC50 of 157 nM, 197 nM, and 208 nM, respectively. Furthermore, GDC-0068 selectively inhibits cell cycle progression and viability of cancer cell lines driven by Akt signaling, including those with defects in the tumor suppressor PTEN, oncogenic mutations in PIK3CA, and amplification of HER2, with strongest effects in HER2+ and Luminal subtypes.
in vivo: Oral administration of GDC-0068 in PC3 prostate tumor xenografts model induces down-regulation of p-PRAS40. In BT474-Tr xenografts, GDC-0068 treatment reduces pS6 and peIF4G levels, re-localizes FOXO3a to nucleus, and induces feedback upregulation of HER3 and pERK. Administration of GDC-0068 exhibits potent antitumor efficacy in multiple xenograft tumor models, including the PTEN-deficient prostate cancer models LNCaP and PC3, the PIK3CA H1047R mutant breast cancer model KPL-4, and MCF7-neo/HER2 tumor model.

Chemical Information

M.Wt 458.0 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C24H32ClN5O2
CAS No 1001264-89-6
Solvent & Solubility

DMSO > 80 mg/mL Ethanol > 80 mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.1834 mL 10.9170 mL 21.8341 mL
5 mM 0.4367 mL 2.1834 mL 4.3668 mL
10 mM 0.2183 mL 1.0917 mL 2.1834 mL

Clinical Information of GDC-0068

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
GDC-0068 Genentech Inc Hormone refractory prostate cancer 31-DEC-11 31-JAN-16 Phase 2 28-NOV-13
Genentech Inc Advanced solid tumor 30-APR-12 31-AUG-14 Phase 1 07-NOV-13
Genentech Inc Solid tumor 31-MAR-10 31-JAN-13 Phase 1 07-NOV-13
Genentech Inc; PPD Development (S) Pte Ltd Metastatic stomach cancer 31-AUG-13 31-AUG-15 Phase 2 28-NOV-13
Genentech Inc Advanced solid tumor 31-JUL-11 31-MAR-13 Phase 1 07-NOV-13

References on GDC-0068

Availability and price:
Stock : in stock
We offer significant discount for larger quantity order.
For quotation, question, and order, please send email to

Related Products :

Online service